Evidence map›Paper›PMID 32495227›Full record

ReviewClinical rheumatology2020

Hypereosinophilic syndrome-a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy.

Emőke Šteňová, Lenka Tarabčáková, Pavel Babál, Stela Kašperová

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. JAK inhibitors for asthma.The Journal of allergy and clinical immunology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Emőke Šteňová1st Department of Internal Medicine, Faculty of Medicine, Comenius University in Bratislava and University Hospital Bratislava, Staré Mesto, Mickiewiczova 13, 813 69, Bratislava, Slovakia. e.stenova@hotmail.com.ORCID https://orcid.org/0000-0001-6595-2959
Lenka TarabčákováDepartment of Rheumatology, Saint Michael's Hospital, Bratislava, Slovakia.
Pavel BabálInstitute of Pathological Anatomy, Faculty of Medicine, Comenius University in Bratislava and University Hospital Bratislava, Bratislava, Slovakia.
Stela Kašperová1st Department of Internal Medicine, Faculty of Medicine, Comenius University in Bratislava and University Hospital Bratislava, Staré Mesto, Mickiewiczova 13, 813 69, Bratislava, Slovakia.
University Hospital Bratislava · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophilia is uncommon in early rheumatoid arthritis (RA). The most frequent causes of hypereosinophilia during RA treatment are atopic eczema, allergy, helminth infection, haematological malignancy and drug-associated complications. The pathogenesis of this abnormality associated with anti-cytokine therapy is still unknown. We report the case of a young woman with RA and eosinophilia accompanied by systemic symptoms such as dyspnoea, fluid retention and eosinophilic vasculitis. An interesting observation was the persistence of eosinophilia during treatment with various biologics and its normalization after switching to the Janus kinase inhibitor baricitinib.

Indexed as

Arthritis, RheumatoidHypereosinophilic SyndromeJanus Kinase InhibitorsCytokinesFemaleHumansCytokinesJanus Kinase InhibitorsAnti-cytokine therapyBaricitinibEosinophiliaRheumatoid arthritisVasculitis

Identifiers

PMID32495227
OpenAlexW3030923357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.